trending digital currency, Knowledge

Pfizer announced an increase in its quarterly dividend, and American pharmaceutical giant Pfizer said on Thursday that it would increase its quarterly dividend by 2.4%, from 42 cents to 43 cents per share. The new dividend is equivalent to $1.72 per year, which means that the annual yield is about 6.8%. Albert Bourla, CEO of Pfizer, said that the dividend increase highlighted the company's strong financial performance, execution and commitment to return capital to shareholders.Russian Intelligence Agency: NATO is worried about Russia's statement about the western participation in the attack on Russia. The Russian Foreign Intelligence Agency issued a statement on the 12th local time, saying that according to the information obtained by the bureau, NATO headquarters is extremely worried about Russia's statement that the United States, Britain and France are directly involved in using western long-range weapons to attack deep areas of Russia. NATO legal experts worry that Russia may accuse western countries of armed aggression against Russia.Haitong Securities: The moderate price reduction of traditional Chinese medicine varieties continues. The domestic pharmaceutical industry is expected to set off a wave of mergers and acquisitions. Haitong Securities released a research report saying that the moderate price reduction of traditional Chinese medicine varieties continues. In 2024, the traditional Chinese medicine industry was under pressure due to the pressure of pharmacy terminal sales and inventory pressure, and it is expected to return to a good situation in the next 25 years. In addition, the continuous technological changes in the pharmaceutical industry, the development of IPO to mergers and acquisitions and the promotion of corporate governance optimization at the shareholder level are the main reasons for promoting mergers and acquisitions in the industry. In terms of fields, mergers and acquisitions are expected to occur intensively in sub-sectors such as medical devices, Chinese medicine, medical services, blood products and scientific research services.

Morgan Stanley called concerns about South Korean financial stocks "excessive". Morgan Stanley said that recent political developments have hit South Korean financial stocks particularly hard because people are worried that reform efforts may be delayed and the risk of tightening supervision.Japanese and Korean stock markets opened lower, with the Nikkei 225 index down 0.56% at 39,624.05. South Korea's KOSPI index opened down 0.3% to 2,473.75 points.Onlikon: Compound α-keto acid tablets are planned to be selected for the tenth batch of national centralized drug procurement. Onlikon announced on December 13, and on December 12, the company participated in the bidding for the tenth batch of national centralized drug procurement organized by the National Drug Joint Procurement Office. After the bid opening and evaluation by the Joint Procurement Office, the company plans to select this centralized drug procurement. The indication of that medicine is to prevent and treat the damage caused by metabolic disorder in protein due to chronic renal insufficiency. The drug is a national medical insurance catalogue product, with an annual sales of 218,900 yuan in 2023, accounting for 0.01% of the company's annual operating income in 2023.

Pfizer announced an increase in its quarterly dividend, and American pharmaceutical giant Pfizer said on Thursday that it would increase its quarterly dividend by 2.4%, from 42 cents to 43 cents per share. The new dividend is equivalent to $1.72 per year, which means that the annual yield is about 6.8%. Albert Bourla, CEO of Pfizer, said that the dividend increase highlighted the company's strong financial performance, execution and commitment to return capital to shareholders.Haitong Securities: The moderate price reduction of traditional Chinese medicine varieties continues. The domestic pharmaceutical industry is expected to set off a wave of mergers and acquisitions. Haitong Securities released a research report saying that the moderate price reduction of traditional Chinese medicine varieties continues. In 2024, the traditional Chinese medicine industry was under pressure due to the pressure of pharmacy terminal sales and inventory pressure, and it is expected to return to a good situation in the next 25 years. In addition, the continuous technological changes in the pharmaceutical industry, the development of IPO to mergers and acquisitions and the promotion of corporate governance optimization at the shareholder level are the main reasons for promoting mergers and acquisitions in the industry. In terms of fields, mergers and acquisitions are expected to occur intensively in sub-sectors such as medical devices, Chinese medicine, medical services, blood products and scientific research services.Warner Bros. Discovery will be reorganized into two major departments. Warner Bros. Discovery said that it will be reorganized into two operating departments, one focusing on traditional cable TV business and the other focusing on streaming media and studios, which may pave the way for the company's future transactions. Warner Bros. Exploration said that it will merge its current Max and Discovery+ streaming media services and HBO departments with another department including Warner Bros.' film and television production business.